On a video call with the guy who ran the latest interview,
On a video call with the guy who ran the latest interview, Dr. Randy (This was a few weeks ago and featured just Dr. Randy and the interviewer) said he'd been in talks with Cytodyn who had just agreed to provide the drug at a reduced price. The interviewer kept pushing about cost but Dr. Randy employed a Detroit Lions-style defense, the bend but don't break. You may know it as the "Prevent".
He admitted that the price would bring LL to the market at a 20-25% discount to a course of RemDeceiver (Trademark Pending). The interviewer pushed further and started doing the calculations. He mentioned that a course of RemDeceiver (Trademark Pending) was just over 10k and then noted that a course of Vyrologix (Trademark already out and getting stank on its downlow, probably with Famvir) must then fall somewhere around $8,500. Dr. Randy also stated in that interview that LL was a 4-dose therapy.
I'll let you do the math on 4 doses and come up with the price per vial because I'm too drunk to taste this chicken.
I don't disagree with you that we should do everything in our power to maximize this opportunity, but you can't set a precedent that LL is cheap. It's our only product. Nader gave away a fair share of doses and now he's (via our best evidence in the referenced video) pricing it 20-25% less than, and I hate to type this because RemDeceiver (Trademark Pending) is a fucking turd...the standard of care.
This is more than reasonable, and by the time the bulk of your average Joes (Filipino Joes, which I think just translates as Joes) need Leronlimab the access will be coming via government supported EUA.
Long story short, he's doing what you want him to while maintaining our best interests moving forward.
Yours virtually,
EveningRespert
19
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
Top 5 Most Recently Viewed Articles
The Opening Ceremony of the 2025 Special Olympics World Winter Games In a grand celebration last night, the lights illuminated the Inalpi Arena, marking the commencement of the 2025 Special Olympics World Winter Games in Turin. This event is poised to become the largest sports and humanitarian gathering of the year. With the lighting of the "Flame of Hope," over 1,500...
Continue Reading
Discover the Joy of Pet Ownership Among Older Canadians Pet ownership can transform lives, and for older Canadians, the companionship of a furry friend offers numerous emotional and physical benefits. According to a recent survey by Ipsos for HomeEquity Bank, it has become evident that many Canadians aged 55 and over understand the significant value of sharing their lives...
Continue Reading
Reputation on the Line Nothing shakes the confidence of hospitals like a recall. You know how it is—one day, everything's rolling along fine, and then BAM, safety issues pop up like bad news at a family dinner. Take Salus Scientific, for instance. They’re standing firm against the wave of issues unraveling other companies in radiation protection gear. They’ve got a...
Continue Reading
Investigation into Potential Violations of Securities Laws Halper Sadeh LLC, a dedicated investor rights law firm, has launched an investigation into several companies regarding potential breaches of fiduciary duties and violations of federal securities laws. This initiative particularly aims to benefit shareholders of Old Point Financial Corporation, ProAssurance...
Continue Reading
Lawsuits Target Leading Oral Health Brands Recent legal troubles have emerged for Procter & Gamble and Colgate-Palmolive regarding their children's oral care products. Parents are voicing their concerns through multiple lawsuits against these industry giants, claiming that fluoride in toothpaste and mouth rinses poses health risks for young children. Key Products Under...
Continue Reading